Damora Therapeutics (DMRA) Change in Accured Expenses (2019 - 2026)
Damora Therapeutics posted quarterly Change in Accured Expenses of $3.6 million for Q1 2026, up 854.11% year-on-year from $377000.0 in Q1 2025, and up 2076.37% on a QoQ basis from -$182000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Change in Accured Expenses data on file, last reported at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 854.11% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 428.94% YoY), and the FY2025 full-year result was $1.1 million, up 135.01% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $3.6 million, up from -$182000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.6 million in Q1 2026 and bottomed at -$3.8 million in Q4 2023.
- The 5-year median for Change in Accured Expenses is $377000.0 (2025), against an average of $169882.4.
- The widest annual swing landed in 2023, when Change in Accured Expenses slumped 606.02%; it then soared 854.11% in 2026.
- A 5-year view of Change in Accured Expenses shows it stood at $747000.0 in 2022, then plunged by 606.02% to -$3.8 million in 2023, then surged by 70.93% to -$1.1 million in 2024, then jumped by 83.44% to -$182000.0 in 2025, then soared by 2076.37% to $3.6 million in 2026.
- The last three Change in Accured Expenses figures came in at $3.6 million (Q1 2026), -$182000.0 (Q4 2025), and $230000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.60 Mn |
| Mar 31, 2026 | 3.60 Mn |
| Dec 31, 2025 | -182,000.00 |
| Dec 31, 2025 | -182,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Jun 30, 2025 | 674,000.00 |
| Jun 30, 2025 | 674,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Dec 31, 2024 | -1.10 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | 411,000.00 |
| Jun 30, 2024 | 411,000.00 |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Dec 31, 2023 | -3.78 Mn |
| Sep 30, 2023 | -1.19 Mn |
| Sep 30, 2023 | -1.19 Mn |
| Jun 30, 2023 | -1.14 Mn |
| Jun 30, 2023 | -1.14 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 747,000.00 |
| Dec 31, 2022 | 747,000.00 |
| Sep 30, 2022 | 2.13 Mn |
| Sep 30, 2022 | 2.13 Mn |
| Jun 30, 2022 | 729,000.00 |
| Jun 30, 2022 | 729,000.00 |
| Mar 31, 2022 | 1.06 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | -719,000.00 |
| Dec 31, 2021 | -719,000.00 |
| Sep 30, 2021 | 617,000.00 |
| Sep 30, 2021 | 617,000.00 |
| Jun 30, 2021 | -626,000.00 |
| Jun 30, 2021 | -626,000.00 |
| Mar 31, 2021 | 1.00 Mn |
| Mar 31, 2021 | 1.00 Mn |
| Dec 31, 2020 | -1.12 Mn |
| Dec 31, 2020 | -1.12 Mn |
| Sep 30, 2020 | 2.00 Mn |
| Sep 30, 2020 | 2.00 Mn |
| Jun 30, 2020 | -2.13 Mn |
| Jun 30, 2020 | -2.13 Mn |
| Mar 31, 2020 | -890,000.00 |
| Mar 31, 2020 | -890,000.00 |
| Dec 31, 2019 | 698,000.00 |
| Dec 31, 2019 | 698,000.00 |